Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test
Arthritis Care & Research · 2023-07 · 75 (7) · 1595-1601
DOI: 10.1002/acr.24990 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 23.01.2023. Verfasst von Ai Li Yeo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Monash University and Monash Health, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Rheumatic Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Simultaneous antibody testing during screening for autoimmune conditions is discouraged. The incidence of positive extractable nuclear antigen (ENA) in the setting of a negative antinuclear antibody (ANA) has been reported as low. Our objective was to characterize the frequency of diagnosis of new ANA‐associated rheumatic disease (AARD) in the setting of a negative ANA with a positive ENA.
Methods
This was a 7‐year retrospective study from a multicenter tertiary health network in Australia. Clinical information was sought on patients over 18 years old who had a negative ANA but positive ENA test result. Results were extracted from hospital computer systems.
Results
From March 19, 2011, to July 23, 2018, ENA testing was ordered simultaneously with an ANA test on 4,248 occasions in 3,484 patients. ANA was positive in 2,520 patients (59.3%) and ENA was positive in 1,980 patients (46.6%). Among positive ANA patients, ENA was positive in 1,563 patients (62.0%). Among 1,728 negative ANA tests, ENA was positive in 417 (24.1%) ( P < 0.001). A total of 328 patients with discordant ANA/ENA results had data available for further analysis, of whom 279 had no pre‐established rheumatologic condition. A new AARD was diagnosed in 17 of 279 patients, yielding a positive predictive value of 6.09% (95% confidence interval 3.59–9.58).
Conclusion
Despite the higher‐than‐expected incidence of positive ENA in the setting of a negative ANA, the yield of newly diagnosed rheumatic diseases was low. Our findings support the stepwise addition of ENA requests when an ANA test result is positive and clinical suspicion of an AARD is high.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Monash University and Monash Health, Clayton, Victoria, Australia.
ORCID-Profile: Ai Li Yeo, Eric Morand
Zitieren
APA
Yeo, A. L., Ojaimi, S., Le, S., Leech, M., & Morand, E. (2023). Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test. Arthritis Care & Research, 75(7), 1595-1601. https://doi.org/10.1002/acr.24990
Vancouver
Yeo AL, Ojaimi S, Le S, Leech M, Morand E. Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test. Arthritis Care & Research. 2023;75(7):1595-1601. doi:10.1002/acr.24990
BibTeX
@article{Yeo2023,
author = {Yeo, Ai Li and Ojaimi, Samar and Le, Suong and Leech, Michelle and Morand, Eric},
title = {Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test},
journal = {Arthritis Care & Research},
year = {2023},
volume = {75},
number = {7},
pages = {1595--1601},
doi = {10.1002/acr.24990}
}
EUVIMED